FDA approves Rinvoq as first oral therapy for moderate to severe Crohn’s disease

The FDA has approved AbbVie’s Rinvoq as a once-day pill intended for the treatment of adult patients with moderate to severe Crohn’s disease who are intolerant, or have had an inadequate response, to one or more TNF inhibitors.Upadacitinib (Rinvoq, AbbVie)v is now indicated for both Crohn’s disease and ulcerative colitis. Additionally, this decision marks the drug’s seventh FDA approval across gastroenterology, dermatology and rheumatology.“AbbVie recognizes the need for more treatment options for Crohn’s disease that can help address both rapid relief ofRead More